Bolt Biotherapeutics Market Cap ($8.97 Million)
Market Cap & Net Worth: Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics market cap. Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $8.97 Million ($8.97 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27213 globally and #5654 in its home market, demonstrating a -0.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bolt Biotherapeutics's stock price $6.57 by its total outstanding shares 1921567 (1.92 Million). Also see BOLT cash generation efficiency for how efficiently the company converts equity into cash flow.
Bolt Biotherapeutics Market Cap History (2021–2026)
Bolt Biotherapeutics market cap history from 2021 to 2026. Data shows change from $9.42 Million to $12.62 Million (-24.15% CAGR). Check BOLT share price today for real-time trading data and today's change.
Index Memberships
Bolt Biotherapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #766 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2491 of 3165 |
Weight: Bolt Biotherapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bolt Biotherapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bolt Biotherapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BOLT shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.37x
Bolt Biotherapeutics's market cap is 1.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $9.42 Million | $1.26 Million | -$98.59 Million | 7.47x | N/A |
| 2022 | $2.50 Million | $5.73 Million | -$88.10 Million | 0.44x | N/A |
| 2023 | $2.15 Million | $7.88 Million | -$69.20 Million | 0.27x | N/A |
| 2024 | $1.03 Million | $7.69 Million | -$63.12 Million | 0.13x | N/A |
| 2025 | $10.51 Million | $7.70 Million | -$33.38 Million | 1.37x | N/A |
Competitor Companies of BOLT by Market Capitalization
Companies near Bolt Biotherapeutics in the global market cap rankings as of November 4, 2026. Also see how large is Bolt Biotherapeutics's balance sheet for a full breakdown of the balance sheet.
Key companies related to Bolt Biotherapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Bolt Biotherapeutics (2021–2026)
Market capitalization of Bolt Biotherapeutics from 2021 to today. Between 2021 and today, Bolt Biotherapeutics's market cap moved from $9.42 Million to $ 12.62 Million, with a yearly change of -24.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.62 Million | +20.15% |
| 2025 | $10.51 Million | +921.87% |
| 2024 | $1.03 Million | -52.22% |
| 2023 | $2.15 Million | -13.85% |
| 2022 | $2.50 Million | -73.47% |
| 2021 | $9.42 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Bolt Biotherapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.97 Million USD |
| MoneyControl | $8.97 Million USD |
| MarketWatch | $8.97 Million USD |
| marketcap.company | $8.97 Million USD |
| Reuters | $8.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more